Standard Strategies for First-Line Renal Cell Carcinoma
Yousef Zakharia, MD, discussed standard first-line treatment for renal cell carcinaoma.
Yousef Zakharia, MD, a medical oncologist and clinical associate professor of internal medicine-hematology, oncology, and blood and marrow transplantation in the Department of Internal Medicine at University of Iowa Health Care, discusses standard treatment for renal cell carcinoma (RCC).
Transcript:
0:08 | The current standard of care is either immunotherapy combination with ipilimumab, nivolumab or with immunotherapy plus [tyrosine kinase inhibitor] regimen. And we have 3 different regimens currently are almost routinely used in a first line setting. The reassuring thing that all these regimens are showing consistent efficacy results and almost similar toxicity profile so that we do not try to say one regimen is better than the other.
0:52 | It's basically becomes more of provider preference. You know, there are some subtle differences between those different regimens that might make us pick them over another one in clinic but in a big picture. There are no huge differences.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
